NEW YORK (GenomeWeb News) – Affomix said today that it will collaborate with City of Hope to establish the clinical utility of "digital proteomics" using next-generation sequencers.

As part of the collaboration, Affomix will use its high-throughput, automated antibody-selection technology to provide City of Hope with recombinant antibodies that are designed to be readily tagged with oligonucleotide "zipcodes," making them compatible with next-generation sequencers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.